KR20140130724A - 매트릭스 메탈로프로테이나제 9에 대한 항체 - Google Patents

매트릭스 메탈로프로테이나제 9에 대한 항체 Download PDF

Info

Publication number
KR20140130724A
KR20140130724A KR1020147026786A KR20147026786A KR20140130724A KR 20140130724 A KR20140130724 A KR 20140130724A KR 1020147026786 A KR1020147026786 A KR 1020147026786A KR 20147026786 A KR20147026786 A KR 20147026786A KR 20140130724 A KR20140130724 A KR 20140130724A
Authority
KR
South Korea
Prior art keywords
ser
seq
thr
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147026786A
Other languages
English (en)
Korean (ko)
Inventor
빅토리아 스미스
스코트 매컬리
Original Assignee
길리아드 바이오로직스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리아드 바이오로직스, 인크. filed Critical 길리아드 바이오로직스, 인크.
Publication of KR20140130724A publication Critical patent/KR20140130724A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • C12N9/6491Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24035Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)
    • G01N2333/96491Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020147026786A 2012-02-29 2012-02-29 매트릭스 메탈로프로테이나제 9에 대한 항체 Ceased KR20140130724A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
KR20140130724A true KR20140130724A (ko) 2014-11-11

Family

ID=45816000

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147026786A Ceased KR20140130724A (ko) 2012-02-29 2012-02-29 매트릭스 메탈로프로테이나제 9에 대한 항체

Country Status (23)

Country Link
US (4) US9550836B2 (enExample)
EP (1) EP2820048B1 (enExample)
JP (1) JP6067756B2 (enExample)
KR (1) KR20140130724A (enExample)
CN (1) CN104395345A (enExample)
AP (1) AP2014007907A0 (enExample)
AU (4) AU2012318302C1 (enExample)
BR (1) BR112014021477A2 (enExample)
CA (1) CA2865530C (enExample)
CL (1) CL2014002282A1 (enExample)
CO (1) CO7061040A2 (enExample)
CR (1) CR20140443A (enExample)
EA (1) EA201491575A1 (enExample)
EC (1) ECSP14020504A (enExample)
ES (1) ES2731441T3 (enExample)
HK (1) HK1208036A1 (enExample)
IN (1) IN2014DN08011A (enExample)
MD (1) MD20140107A2 (enExample)
MX (1) MX2014010449A (enExample)
PH (1) PH12014501931A1 (enExample)
SG (1) SG11201405305PA (enExample)
WO (1) WO2013130078A1 (enExample)
ZA (1) ZA201406319B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011293125B2 (en) 2010-08-27 2015-02-05 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9
CA2865501A1 (en) * 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
BR112014021477A2 (pt) 2012-02-29 2018-06-12 Gilead Sciences Inc anticorpos para metaloproteinase de matriz 9
CN106062001A (zh) * 2014-02-27 2016-10-26 吉利德科学公司 基质金属蛋白酶9的抗体及其使用方法
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985295A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
JP2019513737A (ja) 2016-04-08 2019-05-30 ギリアード サイエンシーズ, インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
US10326830B1 (en) * 2016-09-02 2019-06-18 Amazon Technologies, Inc. Multipath tunneling to a service offered at several datacenters
US10894837B2 (en) 2016-12-16 2021-01-19 Université De Bordeaux MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
US10941178B2 (en) 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
WO2019017338A1 (ja) 2017-07-18 2019-01-24 第一三共株式会社 活性型mmp-9結合ペプチド
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN111785321B (zh) * 2020-06-12 2022-04-05 浙江工业大学 一种基于深度卷积神经网络的dna绑定残基预测方法
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DE60042487D1 (de) * 1999-07-13 2009-08-13 Univ Southern California Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
CN1459505A (zh) * 2002-05-21 2003-12-03 赵平 中国汉族人基质金属蛋白酶-9基因重构、表达、纯化及其医学应用
EP1545611B1 (en) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US8957187B2 (en) * 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
WO2008154439A1 (en) * 2007-06-08 2008-12-18 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
US8008445B2 (en) * 2008-03-03 2011-08-30 Dyax Corp. Metalloproteinase 9 binding proteins
JP2011517320A (ja) * 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ9結合タンパク質およびメタロプロテアーゼ2結合タンパク質
EP2350305A4 (en) * 2008-10-22 2013-03-06 Dyax Corp COMBINATION TREATMENTS WITH PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISEASES
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2011092700A1 (en) * 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
AU2011293125B2 (en) 2010-08-27 2015-02-05 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9
BR112014021477A2 (pt) 2012-02-29 2018-06-12 Gilead Sciences Inc anticorpos para metaloproteinase de matriz 9
CA2865501A1 (en) 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
WO2013130078A1 (en) 2013-09-06
AU2015242967B2 (en) 2017-08-24
HK1205153A1 (en) 2015-12-11
SG11201405305PA (en) 2014-09-26
US11634505B2 (en) 2023-04-25
AU2012318302A1 (en) 2013-09-19
AU2015242967A1 (en) 2015-11-05
EA201491575A1 (ru) 2015-01-30
AU2017216508B2 (en) 2019-03-07
BR112014021477A2 (pt) 2018-06-12
US20170183421A1 (en) 2017-06-29
NZ629888A (en) 2017-02-24
MD20140107A2 (ro) 2015-03-31
US20190127486A1 (en) 2019-05-02
MX2014010449A (es) 2015-02-10
EP2820048A1 (en) 2015-01-07
IN2014DN08011A (enExample) 2015-05-01
ES2731441T3 (es) 2019-11-15
JP6067756B2 (ja) 2017-01-25
CA2865530C (en) 2019-02-19
AP2014007907A0 (en) 2014-08-31
AU2012318302C1 (en) 2017-06-15
US10800857B2 (en) 2020-10-13
CO7061040A2 (es) 2014-09-19
AU2017261626A1 (en) 2017-12-07
US9550836B2 (en) 2017-01-24
ECSP14020504A (es) 2015-09-30
CN104395345A (zh) 2015-03-04
US20150140580A1 (en) 2015-05-21
AU2012318302B2 (en) 2016-08-18
US20210054101A1 (en) 2021-02-25
CA2865530A1 (en) 2013-09-06
PH12014501931A1 (en) 2014-11-24
AU2017216508A1 (en) 2017-08-31
HK1208036A1 (en) 2016-02-19
ZA201406319B (en) 2016-02-24
JP2015514394A (ja) 2015-05-21
CR20140443A (es) 2014-11-17
EP2820048B1 (en) 2019-04-17
CL2014002282A1 (es) 2015-02-20

Similar Documents

Publication Publication Date Title
US11634505B2 (en) Antibodies to matrix metalloproteinase 9
KR101930179B1 (ko) 매트릭스 메탈로프로테이나제 9에 대한 항체
AU2015201367B2 (en) Antibodies to matrix metalloproteinase 9
JP2018082720A (ja) マトリックスメタロプロテイナーゼ9に対する抗体
JP2016106147A (ja) マトリックスメタロプロテイナーゼ9に対する抗体
HK1205153B (en) Antibodies to matrix metalloproteinase 9
NZ629888B2 (en) Antibodies to matrix metalloproteinase 9

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140924

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180619

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180619

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I